Shares of Pfenex (NYSEAMERICAN:PFNX) were up 1.3% on Wednesday . The stock traded as high as $8.42 and last traded at $7.60. Approximately 1,666 shares changed hands during trading, a decline of 99% from the average daily volume of 123,750 shares. The stock had previously closed at $7.70.
Several analysts have weighed in on PFNX shares. William Blair reissued an “outperform” rating on shares of Pfenex in a report on Friday, March 16th. Zacks Investment Research upgraded Pfenex from a “hold” rating to a “buy” rating and set a $5.75 target price for the company in a research report on Thursday, March 22nd. Finally, Barclays set a $8.00 target price on Pfenex and gave the stock a “buy” rating in a research report on Thursday, March 29th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Pfenex presently has a consensus rating of “Hold” and an average price target of $7.67.
Pfenex (NYSEAMERICAN:PFNX) last issued its quarterly earnings data on Thursday, March 15th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.22 by $0.01. Pfenex had a negative return on equity of 63.57% and a negative net margin of 175.52%. The business had revenue of $17.91 million during the quarter, compared to analyst estimates of $5.00 million.
Pfenex Company Profile
Pfenex Inc, a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. The company's lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that are in Phase I study.
Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.